An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

World No Tobacco Day is a good time to revisit tobacco's devastating impact on health, finances, and livelihoods, and see how ...

World No Tobacco Day 2025 theme. The theme for World No Tobacco Day 2025 is 'Bright products. Dark intentions. Unmasking the Appeal' which focuses on highlighting the hidden dange ...

Chronic obstructive pulmonary disease (COPD) affects millions of Americans, with new data from the National Center for Health Statistics showing the condition becomes increasingly common as people age ...

Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...

Children and adolescents with asthma are especially vulnerable. Exposure to e-cigarette aerosols can trigger asthma attacks, reduce medication effectiveness, impair lung function, and slow lung ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

President Donald Trump gathered dozens of hard-hat-clad coal miners around him in the White House East Room. He joked about ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Chest radiographs of 101 patients with chronic airflow obstruction were assessed for evidence of over-inflation (increased retrosternal space, low diaphragm, and increased total lung capacity), ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.